LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system. The company also provides carotid shunts that temporarily shunt the blood to the brain during the removal of plaque from the carotid artery in a carotid endarterectomy surgery; powered phlebectomy devices to remove varicose veins; and radiopaque tape, a medical-grade tape applied to the skin that enables interventionists to cross-refer between the inside and the outside of a patient's body, and allows them to locate tributaries or lesions beneath the skin. In addition, it offers remote endarterectomy devices to remove plaque from arteries in the leg; valvulotomes, which cut valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and vascular grafts to bypass or replace diseased arteries. Further, the company provides vascular patches, which are used for closure of vessels after surgical intervention; closure systems to attach vessels to one another with titanium clips instead of sutures; and surgical glue. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.
IPO Year: 2006
Exchange: NASDAQ
Website: lemaitre.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/15/2024 | $96.00 | Neutral | Cantor Fitzgerald |
| 8/2/2024 | $85.00 → $105.00 | Buy | Lake Street |
| 5/31/2024 | $100.00 | Buy | ROTH MKM |
| 4/26/2024 | $59.00 → $75.00 | Hold → Buy | Stifel |
| 2/6/2024 | Sector Weight | KeyBanc Capital Markets | |
| 10/23/2023 | $60.00 | Mkt Outperform | JMP Securities |
| 9/6/2023 | $70.00 | Outperform | Oppenheimer |
| 8/3/2023 | $63.00 → $67.00 | Buy → Hold | Jefferies |
| 5/3/2023 | $62.00 | Mkt Perform → Outperform | Barrington Research |
| 10/28/2022 | Outperform → Mkt Perform | Barrington Research |
Bridget Ross brings extensive experience in MedTech development and services;Joins advisory board of healthcare, logistics, capital markets and innovation leaders VANCOUVER, BC, March 23, 2021 /PRNewswire/ - Maitri Health Technologies Corp. ("Maitri") (CSE: MTEC) (FRA: D84), a global platform for healthcare supply security, today announced the appointment of Bridget Ross to its Advisory Board. Ms. Ross is currently CEO of ChroniSense Medical, Ltd., an Israel-based MedTech company and maker of wearable, medical-grade disease management devices. Ms. Ross serves as a Board Director for LeMaitre Vascular Inc. (NASDAQ: LMAT) and as a mentor for early stage MedTech companies through MassMEDIC and
4 - LEMAITRE VASCULAR INC (0001158895) (Issuer)
4 - LEMAITRE VASCULAR INC (0001158895) (Issuer)
4 - LEMAITRE VASCULAR INC (0001158895) (Issuer)
4 - LEMAITRE VASCULAR INC (0001158895) (Issuer)
4 - LEMAITRE VASCULAR INC (0001158895) (Issuer)
4 - LEMAITRE VASCULAR INC (0001158895) (Issuer)
4 - LEMAITRE VASCULAR INC (0001158895) (Issuer)
4 - LEMAITRE VASCULAR INC (0001158895) (Issuer)
4 - LEMAITRE VASCULAR INC (0001158895) (Issuer)
4 - LEMAITRE VASCULAR INC (0001158895) (Issuer)
BURLINGTON, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- LeMaitre (NASDAQ:LMAT), a provider of vascular devices, implants, and services, reported Q3 2024 results, announced a $0.16/share quarterly dividend, and provided guidance. Q3 2024 Financial Results Sales $54.8mm, +16% (+16% organic) vs. Q3 2023Gross margin 67.8%, +280 bpsOp. income $13.1mm, +43%Op. margin 24%Earnings per diluted share $0.49, +46%Cash up $10.8mm sequentially to $123.9mm Grafts (+24%), patches (+13%) and carotid shunts (+18%) drove Q3 sales growth. APAC sales increased 24%, EMEA 22% and the Americas 12%. The gross margin increased to 67.8% (vs. 65.0% in Q3 2023), driven by price increases and manufacturing efficiencie
BURLINGTON, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that it will release its third quarter 2024 financial results on Thursday, October 31, 2024, after the market close. The company has scheduled a conference call for 5:00 PM ET the same day to discuss the results, business highlights, and company outlook. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay through a webcast at www.lemaitre.com/investor. About LeMaitre LeMaitre is a provider of devices, implants, and
BURLINGTON, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- LeMaitre (NASDAQ:LMAT), a provider of vascular devices, implants and services, today reported Q2 2024 results, announced a $0.16/share quarterly dividend and provided guidance. Q2 2024 Financial Results Sales $55.8mm, +11% (+12% organic) vs. Q2 2023 Gross margin 68.9%, +490 bpsOp. income $14.4mm, +52%Op. margin 26%Net income $11.8mm, +46%Earnings per diluted share $0.52, +44%Cash up $4.8mm sequentially to $113.1mm Allografts (+30%), bovine patches (+12%) and carotid shunts (+22%) led Q2 sales growth. APAC sales increased 20%, EMEA 13% and the Americas 10%. The gross margin increased to 68.9% (vs. 64.0% in Q2 2023), driven by manufac
BURLINGTON, Mass., July 16, 2024 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that it will release its second quarter 2024 financial results on Thursday, August 1, 2024, after the market close. The company has scheduled a conference call for 5:00 PM ET the same day to discuss the results, business highlights, and company outlook. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay through a webcast at www.lemaitre.com/investor. About LeMaitre LeMaitre is a provider of devices, implants, and s
BURLINGTON, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- LeMaitre (NASDAQ:LMAT), a provider of vascular devices, implants and services, today reported Q1 2024 results, announced a $0.16/share quarterly dividend and provided guidance. Q1 2024 Financial Results Sales $53.5mm, +14% (+11% organic) vs. Q1 2023 Gross margin 68.6%, +300 bpsOp. income $11.9mm, +51%Op. margin 22%Net income $9.9mm, +64%Earnings per diluted share $0.44, +62%Cash up $3.2mm sequentially to $108.3mm Allografts (+31%), bovine patches (+13%), carotid shunts (+27%) and distributed porcine patches drove Q1 sales. APAC sales increased 44%, EMEA 17% and the Americas 10%. The gross margin increased to 68.6% in Q1 (vs. 65.6% in
BURLINGTON, Mass., April 19, 2024 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that it will release its first quarter 2024 financial results on Thursday, May 2, 2024, after the market close. The company has scheduled a conference call for 5:00 PM ET the same day to discuss the results, business highlights, and company outlook. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay through a webcast at www.lemaitre.com/investor. About LeMaitre LeMaitre is a provider of devices, implants, and serv
BURLINGTON, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- LeMaitre (NASDAQ:LMAT), a provider of vascular devices, implants and services, today reported Q4 2023 results, announced a $0.16/share quarterly dividend and provided guidance. Q4 2023 Financial Results Sales $48.9mm, +19% (+14% organic) vs. Q4 2022Gross margin 68.1%, +450 bpsOp. income $10.2mm, +46%Op. margin 21%Net income $8.5mm, +50%Earnings per diluted share $0.38, +49%Cash up $8.1mm sequentially to $105.1mm Bovine patches (+18%), allografts (+52%), valvulotomes (+12%), carotid shunts (+16%) and distributed porcine patches drove Q4 sales. EMEA sales increased 21%, the Americas 20% and APAC 11%. The gross margin increased to 68.1%
BURLINGTON, Mass., Feb. 13, 2024 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that it will release its fourth quarter 2023 financial results on Tuesday, February 27, 2024, after the market close. The company has scheduled a conference call for 5:00 PM ET the same day to discuss the results, business highlights, and company outlook. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay through a webcast at www.lemaitre.com/investor. About LeMaitre LeMaitre is a provider of devices, implants, and
BURLINGTON, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- LeMaitre (NASDAQ:LMAT), a provider of vascular devices, implants and services, today reported Q3 2023 results, announced a $0.14/share quarterly dividend and provided guidance. Q3 2023 Financial Results Sales $47.4mm, +21% (+16% organic) vs. Q3 2022Gross margin 65.0%, +80 bpsOp. income $9.2mm, +49%Op. margin 19%Net income $7.5mm, +38%Earnings per diluted share $0.33, +36%Cash up $6.8mm to $97.0mm Bovine patches (+22%), valvulotomes (+27%), bovine grafts (+15%) and carotid shunts (+24%) drove Q3 sales. APAC sales increased 30%, EMEA 24% and the Americas 20%. The gross margin increased to 65.0% in Q3 (vs. 64.2% in Q3 2022) driven large
BURLINGTON, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that it will release its third quarter 2023 financial results on Wednesday, November 1, 2023, after the market close. The company has scheduled a conference call for 5:00 PM EDT the same day to discuss the results, business highlights, and company outlook. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay through a webcast at www.lemaitre.com/investor. About LeMaitre LeMaitre is a provider of dev
BURLINGTON, Mass., Nov. 01, 2024 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that management will be participating in three upcoming investor conferences in November. UBS Global Healthcare Conference Wednesday, November 13, 2024 Terranea Resort, Rancho Palos Verdes, CA David Roberts, President, will present at 7:15 AM PT Stifel's 2024 Healthcare Conference Tuesday, November 19, 2024 Lotte NY Palace Hotel, New York City David Roberts, President, will present at 1:50 PM ET Wolfe Research Healthcare Conference 2024 Wednesday, November 20, 2024 Wolfe Research HQ, New York City David Roberts, President, wi
BURLINGTON, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- LeMaitre (NASDAQ:LMAT), a provider of vascular devices, implants, and services, reported Q3 2024 results, announced a $0.16/share quarterly dividend, and provided guidance. Q3 2024 Financial Results Sales $54.8mm, +16% (+16% organic) vs. Q3 2023Gross margin 67.8%, +280 bpsOp. income $13.1mm, +43%Op. margin 24%Earnings per diluted share $0.49, +46%Cash up $10.8mm sequentially to $123.9mm Grafts (+24%), patches (+13%) and carotid shunts (+18%) drove Q3 sales growth. APAC sales increased 24%, EMEA 22% and the Americas 12%. The gross margin increased to 67.8% (vs. 65.0% in Q3 2023), driven by price increases and manufacturing efficiencie
BURLINGTON, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that it will release its third quarter 2024 financial results on Thursday, October 31, 2024, after the market close. The company has scheduled a conference call for 5:00 PM ET the same day to discuss the results, business highlights, and company outlook. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay through a webcast at www.lemaitre.com/investor. About LeMaitre LeMaitre is a provider of devices, implants, and
BURLINGTON, Mass., Aug. 27, 2024 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that management will be participating in three upcoming investor conferences in September. Morgan Stanley 22nd Annual Global Healthcare ConferenceWednesday, September 4, 2024New York Marriott Marquis, New York, NYDavid Roberts, President, will present at 5:35 PM EST Barrington Research Fall Investment Conference (Virtual)Thursday, September 12, 2024George W. LeMaitre, Chairman & CEO, is scheduled to host a series of 1x1 meetings Cantor Fitzgerald 2024 Global Healthcare ConferenceThursday, September 19, 2024InterContinental New York Barclay Hotel, New York, NYDavid Roberts, Presiden
BURLINGTON, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- LeMaitre (NASDAQ:LMAT), a provider of vascular devices, implants and services, today reported Q2 2024 results, announced a $0.16/share quarterly dividend and provided guidance. Q2 2024 Financial Results Sales $55.8mm, +11% (+12% organic) vs. Q2 2023 Gross margin 68.9%, +490 bpsOp. income $14.4mm, +52%Op. margin 26%Net income $11.8mm, +46%Earnings per diluted share $0.52, +44%Cash up $4.8mm sequentially to $113.1mm Allografts (+30%), bovine patches (+12%) and carotid shunts (+22%) led Q2 sales growth. APAC sales increased 20%, EMEA 13% and the Americas 10%. The gross margin increased to 68.9% (vs. 64.0% in Q2 2023), driven by manufac
BURLINGTON, Mass., July 16, 2024 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that it will release its second quarter 2024 financial results on Thursday, August 1, 2024, after the market close. The company has scheduled a conference call for 5:00 PM ET the same day to discuss the results, business highlights, and company outlook. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay through a webcast at www.lemaitre.com/investor. About LeMaitre LeMaitre is a provider of devices, implants, and s
BURLINGTON, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that George W. LeMaitre, Chairman & CEO, will present at the 2024 Jefferies Global Healthcare Conference on Thursday, June 6, 2024, at 11:00 AM ET at the Marriott Marquis in New York City. About LeMaitre LeMaitre is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. Additional information can be found at www.lemaitre.co
BURLINGTON, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- LeMaitre (NASDAQ:LMAT), a provider of vascular devices, implants and services, today reported Q1 2024 results, announced a $0.16/share quarterly dividend and provided guidance. Q1 2024 Financial Results Sales $53.5mm, +14% (+11% organic) vs. Q1 2023 Gross margin 68.6%, +300 bpsOp. income $11.9mm, +51%Op. margin 22%Net income $9.9mm, +64%Earnings per diluted share $0.44, +62%Cash up $3.2mm sequentially to $108.3mm Allografts (+31%), bovine patches (+13%), carotid shunts (+27%) and distributed porcine patches drove Q1 sales. APAC sales increased 44%, EMEA 17% and the Americas 10%. The gross margin increased to 68.6% in Q1 (vs. 65.6% in
BURLINGTON, Mass., April 19, 2024 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that it will release its first quarter 2024 financial results on Thursday, May 2, 2024, after the market close. The company has scheduled a conference call for 5:00 PM ET the same day to discuss the results, business highlights, and company outlook. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay through a webcast at www.lemaitre.com/investor. About LeMaitre LeMaitre is a provider of devices, implants, and serv
BURLINGTON, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that JJ Pellegrino, Chief Financial Officer, will present virtually at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10, 2024, at 11:30 AM ET. About LeMaitre LeMaitre is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. Additional information can be found at www.lemaitre.com. Contact: Sandr
LeMaitre Vascular (NASDAQ:LMAT) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 2 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 2 0 0 0 2M Ago 1 0 0 0 0 3M Ago 0 0 0 0 0 Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $82.75, along with a high estimate of $100.00 and a low estimate of $75.00. This current averag
Roth MKM analyst Jason Wittes reinstates LeMaitre Vascular (NASDAQ:LMAT) with a Buy and announces $100 price target.
Barrington Research analyst Michael Petusky maintains LeMaitre Vascular (NASDAQ:LMAT) with a Outperform and raises the price target from $69 to $79.
JMP Securities analyst Daniel Stauder maintains LeMaitre Vascular (NASDAQ:LMAT) with a Market Outperform and raises the price target from $72 to $77.
LeMaitre Vascular (NASDAQ:LMAT) reported quarterly earnings of $0.44 per share which beat the analyst consensus estimate of $0.38 by 15.79 percent. This is a 62.96 percent increase over earnings of $0.27 per share from the same period last year. The company reported quarterly sales of $53.478 million which beat the analyst consensus estimate of $51.506 million by 3.83 percent. This is a 13.60 percent increase over sales of $47.075 million the same period last year.
Stifel analyst Rick Wise upgrades LeMaitre Vascular (NASDAQ:LMAT) from Hold to Buy and raises the price target from $59 to $75.
Barrington Research has decided to maintain its Outperform rating of LeMaitre Vascular (NASDAQ:LMAT) and raise its price target from $66.00 to $69.00. Shares of LeMaitre Vascular are trading up 3.28% over the last 24 hours, at $64.15 per share. A move to $69.00 would account for a 7.56% increase from the current share price. About LeMaitre Vascular LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are primarily used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes the large
10-Q - LEMAITRE VASCULAR INC (0001158895) (Filer)
8-K - LEMAITRE VASCULAR INC (0001158895) (Filer)
8-K - LEMAITRE VASCULAR INC (0001158895) (Filer)
S-8 - LEMAITRE VASCULAR INC (0001158895) (Filer)
10-Q - LEMAITRE VASCULAR INC (0001158895) (Filer)
8-K - LEMAITRE VASCULAR INC (0001158895) (Filer)
8-K - LEMAITRE VASCULAR INC (0001158895) (Filer)
SD - LEMAITRE VASCULAR INC (0001158895) (Filer)
10-Q - LEMAITRE VASCULAR INC (0001158895) (Filer)
8-K - LEMAITRE VASCULAR INC (0001158895) (Filer)
Cantor Fitzgerald initiated coverage of Lemaitre Vascular with a rating of Neutral and set a new price target of $96.00
Lake Street resumed coverage of Lemaitre Vascular with a rating of Buy and set a new price target of $105.00 from $85.00 previously
ROTH MKM resumed coverage of Lemaitre Vascular with a rating of Buy and set a new price target of $100.00
Stifel upgraded Lemaitre Vascular from Hold to Buy and set a new price target of $75.00 from $59.00 previously
KeyBanc Capital Markets resumed coverage of Lemaitre Vascular with a rating of Sector Weight
JMP Securities initiated coverage of Lemaitre Vascular with a rating of Mkt Outperform and set a new price target of $60.00
Oppenheimer initiated coverage of Lemaitre Vascular with a rating of Outperform and set a new price target of $70.00
Jefferies downgraded Lemaitre Vascular from Buy to Hold and set a new price target of $67.00 from $63.00 previously
Barrington Research upgraded Lemaitre Vascular from Mkt Perform to Outperform and set a new price target of $62.00
Barrington Research downgraded Lemaitre Vascular from Outperform to Mkt Perform
SC 13G - LEMAITRE VASCULAR INC (0001158895) (Subject)
SC 13G/A - LEMAITRE VASCULAR INC (0001158895) (Subject)
SC 13G/A - LEMAITRE VASCULAR INC (0001158895) (Subject)
SC 13G - LEMAITRE VASCULAR INC (0001158895) (Subject)
SC 13G/A - LEMAITRE VASCULAR INC (0001158895) (Subject)
SC 13G/A - LEMAITRE VASCULAR INC (0001158895) (Subject)
SC 13G/A - LEMAITRE VASCULAR INC (0001158895) (Subject)
SC 13G - LEMAITRE VASCULAR INC (0001158895) (Subject)
SC 13G - LEMAITRE VASCULAR INC (0001158895) (Subject)
SC 13G/A - LEMAITRE VASCULAR INC (0001158895) (Subject)